2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference
TSVT Stock | USD 3.71 0.24 6.08% |
Slightly above 62% of 2Seventy Bio's investor base is looking to short. The analysis of the overall investor sentiment regarding 2Seventy Bio suggests that many traders are alarmed. 2Seventy Bio's investing sentiment can be driven by a variety of factors including economic data, 2Seventy Bio's earnings reports, geopolitical events, and overall market trends.
2Seventy |
2seventy bio, Inc. , a leading immune-oncology cell therapy company, announced today that members of the management team will participat
Read at businesswire.com
2Seventy Bio Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards 2Seventy Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
2Seventy Bio Fundamental Analysis
We analyze 2Seventy Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 2Seventy Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 2Seventy Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
2Seventy Bio is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
2Seventy Bio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 2Seventy Bio stock to make a market-neutral strategy. Peer analysis of 2Seventy Bio could also be used in its relative valuation, which is a method of valuing 2Seventy Bio by comparing valuation metrics with similar companies.
Peers
2Seventy Bio Related Equities
INZY | Inozyme Pharma | 9.56 | ||||
PTGX | Protagonist Therapeutics | 2.72 | ||||
KZR | Kezar Life | 2.21 | ||||
REPL | Replimune | 1.58 | ||||
CRNX | Crinetics Pharmaceuticals | 0.97 | ||||
MRSN | Mersana Therapeutics | 0.81 | ||||
RCUS | Arcus Biosciences | 0.11 | ||||
CGEM | Cullinan Oncology | 1.18 | ||||
SRPT | Sarepta Therapeutics | 1.78 | ||||
DAWN | Day One | 1.86 | ||||
ASND | Ascendis Pharma | 2.08 | ||||
PLRX | Pliant Therapeutics | 2.22 | ||||
PBYI | Puma Biotechnology | 3.31 | ||||
STOK | Stoke Therapeutics | 3.63 | ||||
PHAT | Phathom Pharmaceuticals | 3.88 | ||||
IOVA | Iovance Biotherapeutics | 3.91 | ||||
SNDX | Syndax Pharmaceuticals | 3.98 | ||||
RLAY | Relay Therapeutics | 5.74 | ||||
ZNTL | Zentalis Pharmaceuticals | 7.20 |
Additional Tools for 2Seventy Stock Analysis
When running 2Seventy Bio's price analysis, check to measure 2Seventy Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 2Seventy Bio is operating at the current time. Most of 2Seventy Bio's value examination focuses on studying past and present price action to predict the probability of 2Seventy Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 2Seventy Bio's price. Additionally, you may evaluate how the addition of 2Seventy Bio to your portfolios can decrease your overall portfolio volatility.